anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: The purpose of this prospective single blinded randomized controlled trial was to find out whether goal-directed fluid therapy (GDFT) strategy in post-transection period in low central venous pressure (CVP) assisted laparoscopic hepatectomy (LH) has more benefit than traditional fluid strategy.
METHODS: Between April 2020 and Dec 2021, patients who were scheduled for laparoscopic liver resection surgery were eligible to participate in the study. Patients were randomly divided into two groups: control group that received traditional fluid strategy in post-transection period in low CVP assisted laparoscopic hepatectomy and GDFT strategy group that received GDFT strategy in post-transection period. The primary outcome parameter is the incidence of postoperative complications. Secondary outcome parameters include perioperative clinical outcomes, postoperative clinical outcomes, length of hospital stay after surgery, postoperative lactic acid, fluids and vasoactive medications during the operation.
RESULTS: A total of 159 patients in the control group and 160 patients in the GDFT were included. Two groups had no significant difference in the incidence of postoperative complications including pneumonia (P = 0.34), acute kidney injury (P = 0.72), hepatic insufficiency (P = 0.25), pleural effusion (P = 0.08) and seroperitoneum (P = 1.00), respectively. The amount of perioperative urine output is fewer in GDFT group than in the control group (P = 0.0354), while other perioperative variables and postoperative variables were comparable between two groups.
CONCLUSIONS: The results show the implementation of GDFT strategy is not associated with fewer postoperative complications. GDFT strategy did not result in improved outcomes in low CVP-assisted laparoscopic hepatectomy.
The patient device, designed for use by patients of reduced cognitive or physical ability, integrates with the network-based portal, designed for use by family members or nursing staff to customize the user experience of the patient. Using the portal the family member pushes user interface customizations as well as content and applications to be run on the patient device. The family member can also control the patient device remotely via the portal. The patient device collects usage data on the set of customizable interface components, and on the pushed content and applications. These data are sent as feedback to the portal, allowing the portal to show the family member which user interface features, content and applications are being used and which are not. Aggregate data collected via the portal generate ranking metrics used to aid in user interface feature selection.
FIELD: medicine, urology, pediatrics. SUBSTANCE: invention relates to method of treatment of children suffering with enuresis. Method involves carrying out the complex therapy using glycine or taufon in the dose 60-70 mg/kg per 24 h. Administration is carried out in the dose 60-70 mg/kg per 24 h in 3-4 intakes before eating. Treatment duration is 4-7 weeks. Method provides high effect of treatment due to simultaneous effect on sympathetic and glycine- ergic receptors located in bladder sphincter. EFFECT: enhanced effectiveness of treatment. 2 ex
A positive family history is a major independent risk factor for atherosclerosis, and genetic variation is an important aspect of cardiovascular disease research. We identified a heterozygous missense variant p.L245P in the MMP10 gene in two families with premature myocardial infarction using whole-exome sequencing. The aim of this study was to investigate the consequences of this variant using in-silico and functional in-vitro assays. Molecular dynamics simulations were used to analyze protein interactions, calculate free binding energy, and measure the volume of the substrate-binding cleft of MMP10-TIMP1 models. The p.L245P variant showed an altered protein surface, different intra- and intermolecular interactions of MMP10-TIMP1, a lower total free binding energy between MMP10-TIMP1, and a volume-minimized substrate-binding cleft of MMP10 compared to the wild-type. For the functional assays, human THP-1 cells were transfected with plasmids containing MMP10 cDNA carrying the p.L245P and wild-type variant and differentiated into macrophages. Macrophage adhesion and migration assays were then conducted, and pro-inflammatory chemokine levels were evaluated. The p.L245P variant led to macrophages that were more adherent, less migratory, and secreted higher levels of the pro-inflammatory chemokines CXCL1 and CXCL8 than wild-type macrophages. Thus, the p.L245P variant in MMP10 may influence the pathogenesis of atherosclerosis in families with premature myocardial infarction by altering protein - protein interactions, macrophage adhesion and migration, and expression of pro-inflammatory chemokines, which may increase plaque rupture. These results could contribute to the development of selective MMP10 inhibitors and reduce the risk of atherosclerosis in families with a history of premature myocardial infarction.
Group 3 will receive twice daily sham taVNS for 7 days immediately prior to psilocybin dosing. Post-psilocybin dosing, they will receive psychosocial support alone, comprised of an integration session 1 day and 1-week post-psilocybin dosing. They will not receive active or sham taVNS post-psilocybin.
Lactated Ringer's (LR) fluid will be administered to patients randomized to the experimental arm. LR will be used for all fluid boluses and maintenance fluids (supplemental electrolytes are allowed) from time immediately after randomization through 11:59 pm of the next calender day. The determination of when to give fluid, how much fluid to give, how fast to give fluid, and what access to use to administer fluid will remain at the discretion of the treating team.
Tumor histomorphology is crucial for the prognostication of breast cancer outcomes because it contains histological, cellular, and molecular tumor heterogeneity related to metastatic potential. To enhance breast cancer prognosis, we aimed to apply radiomics analysis-traditionally used in 3D scans-to 2D histopathology slides. This study tested radiomics analysis in a cohort of 92 breast tumor specimens for outcome prognosis, addressing -omics dimensionality by comparing models with moderate and high feature counts, using least absolute shrinkage and selection operator for feature selection and machine learning for prognostic modeling. In the test folds, models with radiomics features [area under the curves (AUCs) range 0.799-0.823] significantly outperformed the benchmark model, which only included clinicopathological (CP) parameters (AUC = 0.584). The moderate-dimensionality model with 11 CP + 93 radiomics features matched the performance of the highly dimensional models with 1,208 radiomics or 11 CP + 1,208 radiomics features, showing average AUCs of 0.823, 0.799, and 0.807 and accuracies of 79.8, 79.3, and 76.6%, respectively. In conclusion, our application of deep texture radiomics analysis to 2D histopathology showed strong prognostic performance with a moderate-dimensionality model, surpassing a benchmark based on standard CP parameters, indicating that this deep texture histomics approach could potentially become a valuable prognostic tool.
BACKGROUND: Survivors of critical illness are at increased risk of long-term impairments, referred to as post-intensive care unit (ICU) syndrome (PICS). Post-traumatic stress disorder (PTSD) is common among ICU survivors with reported rates of up to 27%. The prevalence of PTSD among Israeli ICU survivors has not been reported to date.
OBJECTIVES: To evaluate the prevalence of new onset PTSD diagnosed in a post-ICU clinic at a tertiary center in Israel.
METHODS: We conducted a retrospective, single center, cohort study. Data were collected from medical records of all patients who visited the Tel Aviv Sourasky Medical Center post-ICU clinic between October 2017 and June 2020. New onset PTSD was defined as PTSD diagnosed by a certified board psychiatrist during the post-ICU clinic visit. Data were analyzed using descriptive statistics.
RESULTS: Overall, 39 patients (mean age 51 ± 17 years, 15/39 females [38%]) attended the post-ICU clinic during the study period. They were evaluated 82 ± 57 days after hospital discharge. After excluding 7 patients due to missing proper psychiatric analysis, 32 patients remained eligible for the primary analysis. New PTSD was diagnosed in one patient (3%).
CONCLUSIONS: We found lower incidence of PTSD in our cohort when compared to existing literature. Possible explanations include different diagnostic tools and low risk factors rate. Unique national, cultural, and/or religious perspectives might have contributed to the observed low PTSD rate. Further research in larger study populations is required to establish the prevalence of PTSD among Israeli ICU survivors.
Penicillin G benzathine has an extremely low solubility and, thus, the drug is slowly released from intramuscular injection sites. The drug is hydrolyzed to penicillin G. This combination of hydrolysis and slow absorption results in blood serum levels much lower but much more prolonged than other parenteral penicillins.

Intramuscular administration of 300,000 units of penicillin G benzathine in adults results in blood levels of 0.03 to 0.05 units per mL, which are maintained for 4 to 5 days. Similar blood levels may persist for 10 days following administration of 600,000 units and for 14 days following administration of 1,200,000 units. Blood concentrations of 0.003 units per mL may still be detectable 4 weeks following administration of 1,200,000 units.

Approximately 60% of penicillin G is bound to serum protein. The drug is distributed throughout the body tissues in widely varying amounts. Highest levels are found in the kidneys with lesser amounts in the liver, skin, and intestines. Penicillin G penetrates into all other tissues and the spinal fluid to a lesser degree. With normal kidney function, the drug is excreted rapidly by tubular excretion. In neonates and young infants and in individuals with impaired kidney function, excretion is considerably delayed.
A water soluble factor is derived from regenerating nerves, such as the optical nerves of fish, and this factor activates suitable target cells, such as for example glial cells, to produce extracellular proteins. Mainly laminin is thus produced. The factor is a negatively charged protein which has an apparent molecular weight of about 10,000 daltons, determined on a sieving type column. There is also provided a process for the purification of such factor. Furthermore there are provided pharmaceutical compositions which induce regeneration of nerves of the central nervous system of mammals, which contain as actaive ingredient an effective quantity of such purified facator. The effect of this factor on the regeneration of nerves is augmented when the injured site is irradiated with radiation from a low energy He-Ne laser.
RT to brain tumours causes cognitive dysfunction. The extent of RT induced changes in cognitive function and radio-sensitivity of the brain is unknown. RT with protons instead of photons spares the healthy brain tissue more and is believed to reduce the risk of cognitive dysfunction. There is modest knowledge on which parts of the brain the investigators need to spare, to prevent cognitive dysfunction.

The study is a cross sectional study assessing cognitive function in patients with brain tumours previously treated with RT compared to a similar non irradiated group. 104 patients with specified brain tumours from Aarhus University Hospital treated in the period 2006-2016 will be included. The patients will do patient reported outcome (PRO) and undergo neuropsychological assessment with standardized tests: They will do this prior to RT treatment and ½, 1, 3 and 5 years afterwards. The PRO's included measures on quality of life, fatigue, sleep, depression, anxiety, and socio demografica. The standardized tests are: Trail making Test (TMT); Hopkins Verbal Learning Test (HVLT); Controlled Oral Word Association Test (COWAT) - Animals and S; Coding and Digit Span from WAIS-IV; Paced Auditory Serial Addition Test (PASAT). The correlation between cognitive scores and RT dose-volume parameters to specific areas in the brain will be tested.
The invention relates to a medicine for preventing and treating bovine influenza. The medicine is composed of cassia twig, commeline communis, cyrtomium rhizome, radix bupleuri, licorice, coptis, fructus forsythiae, anemarrhena, scabrous elephantfoot herb, notopterygium root, arctium fruit, perilla leaf, dark plum, and kudzu vine root. The medicine is prepared by the following steps: weighing the components mentioned above, decocting, extracting the effective components, then adding fine powder, which is prepared by grinding malt, haw, dried orange peel, rhizoma atractylodis, radix codonopsis, pokeberry root, Chinese angelica, and herba andrographitis, and evenly mixing the effective components and the fine powder so as to obtain the medicine. The symptoms such as fever, and the like of cattle can be effectively released after the application of the medicine, and the final cure rate can reach 100%. Furthermore, the medicine contains an appetite promoter, which can increase the food intake of cattle, and an immunity agent, which can increase the immunity of cattle. The components cooperate with each other to generate a synergetic effect, and the cattle can be quickly cured by the medicine.
PROBLEM TO BE SOLVED: To obtain the subject stimulating agent containing the extract of an alga belonging to the genus Durvillea in the family Durvilleaceae as Phaeophyceae as an active ingredient, having a biological hyaluronic acid synthesis-stimulating action, preventing the generation of wrinkles on skins and high in safety. SOLUTION: This agent for biologically stimulating the synthesis of hyaluronic acid contains the extract of an alga belonging to the genus Durvillea in the family Durvilleaceae as an active ingredient. The alga belonging to the genus Durvillea in the family Durvilleaceae includes Durvillea antarctica. The extract is obtained by extracting the alga with water, a hydrophilic organic solvent, etc., preferably water or its mixture with a lower alcohol such as methanol or ethanol. When the stimulating agent is used e.g. as a preparation for external use for skin, the extract is compounded in an amount of 0.01-30wt.%, preferably 0.01-10wt.%.
The invention discloses a traditional Chinese medicine for treating uterine fibroid. The traditional Chinese medicine comprises the following herbal medicines in parts by weight: 20-30 parts of Chinese angelica, 20-30 parts of Chinese angelica, 20-30 parts of rhizoma cyperi, 20-30 parts of cattail pollen, 20-30 parts of prepared rehmannia root, 10-20 parts of fructus aurantii, 10-20 parts of radix achyranthis bidentatae, 10-20 parts of myrrh, 10-20 parts of white paeony roots, 5-15 parts of spina gleditsiae, 5-15 parts of red flowers, 5-15 parts of ligusticum wallichii and 2-8 parts of cinnamon. The herbal medicines are fried and processed into decoction, tablets or capsules. The daily-taking dosage for a patient is 60g-70g of the original materials. The traditional Chinese medicine is taken three times a day, drunk with an empty belly half an hour before the breakfast, the lunch and the supper, and one course of treatment lasts for one month. By virtue of the treatment with 1-4 courses of treatments, the total effective rate is 98%, the recovery rate is 94% and the recurrence rate is lower than 0.4%.
The invention discloses a preparation method for preparing swan embryos. The method comprises the steps of subjecting swan embryonic stem cells to cell membrane breaking treatment, removing impurities, and extracting to obtain the swan pluripotent embryos. The invention also discloses swan embryos prepared by the above method, and the application of swan embryos. According to the technical scheme of the invention, swan pluripotent embryos are separated from swan embryonic stem cells, and the effects of human embryos can be realized. That means, various cells in a human body are ensured to stay active, and the service lives of working cells are prolonged. Meanwhile, damaged cells are repaired and the functions of cells are recovered. Dormant cells in the human body are activated, and effective working cells are supplemented. Moreover, the attenuation of stem cells themselves is protected and the generation of stem cells is promoted. Dormant stem cells are activated to generate new cells for replacing dead cells. Therefore, the purpose of recovering the internal organs of the human body is realized.
INTRODUCTION: In the perioperative period, regional analgesia techniques may play an increasingly important role in "Enhanced Recovery After Surgery (ERAS)" programs, as they can facilitate recovery. We hypothesized that Erector Spinae Plane (ESP) block could improve regional perfusion, thereby limiting blood lactate increase. Therefore, we aimed to evaluate the effect of ESP block on intraoperative blood lactate levels in patients scheduled for elective on-pump cardiac surgery with ERAS protocol.
METHODS: A total of 68 adult patients scheduled for on-pump cardiac surgery were included. All patients were randomized to the ESP group and the non-ESP group. Blood lactate analyses were performed at intraoperative five-time points. C-Reactive protein (CRP) values were also measured.
RESULTS: Blood lactate values were significantly lower in the ESP group than in the Non-ESP group, at the end of CPB [1.78 (1.23-2.78) mmol L-1 to 2.63 (1.70-3.12) mmol L-1] and during the sternal closure period [1.78 (1.27-2.42) mmol L-1 to 2.40 (2.14-2.80) mmol L-1] (p = 0.039, p = 0.009). In addition, CRP values were significantly lower in the ESP group in the postoperative period [0.048 (0.036-0.105) g L-1 to 0.090 (0.049-0.154) g L-1] (p = 0.035).
CONCLUSIONS: This study showed that preoperative bilateral single-shot ESP block significantly reduces intraoperative final blood lactate and postoperative CRP values. We consider that these results are related to the attenuation of intraoperative hypoperfusion and the alleviation of surgery-related postoperative inflammation. ERAS programs aim to achieve the rapid recovery of patients, a decrease in inflammation, and high-quality analgesia with less opioid consumption. Therefore, our results also prove that it is easier to reach the primary goals of ERAS programs with the application of ESP block in cardiac surgery.
As chronic kidney disease (CKD) continues to increase worldwide, along with the demand for related life-saving therapies, the financial burden of CKD will place an increasing drain on health care systems. Experimental studies showed that glomerular capillary hypertension and impaired sieving function with consequent protein overload play a pathogenic role in the progression of CKD. Consistently, human studies show that proteinuria is an independent predictor of progression and that its reduction is renoprotective. At comparable BP control, inhibitors of the renin-angiotensin system (RAS), including angiotensin converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs), more effectively than non-RAS inhibitor therapy reduce proteinuria, slow progression to ESRD, and even improve the kidney function achieving disease regression in some cases. In participants with diabetes, RAS inhibitors delay the onset of microalbuminuria and its progression to macroalbuminuria, and ACE inhibitors may reduce the excess cardiovascular mortality associated with diabetic renal disease. In addition to RAS inhibitors, however, multimodal approaches including lifestyle modifications and multidrug therapy will be required in most cases to optimize control of the several risk factors for CKD and related cardiovascular morbidity. Novel medications, including proximal tubular sodium - glucose co-transporter -2 (SGLT2 inhibitors - that ameliorate glomerular hyperfiltration and proteinuria and slow renal disease progression in type 2 diabetes by mechanisms apparently independent of improved metabolic control - might help further improve the cost-effectiveness of renoprotective interventions even in non-diabetic CKD. This phase 2, prospective, randomized, cross over, placebo-controlled trial will primarily aim to assess whether the SGLT2 inhibitor dapagliflozin ameliorates hyperfiltration and reduces proteinuria as compared to placebo in patients with non-diabetic CKD, with particular focus on those at highest risk of progression to end stage kidney disease (ESKD) because of severe renal insufficiency (Stage IV CKD) and proteinuria (\>0.5 g/24 hours).
Primary aldosteronism (PA) is occasionally associated with impaired glucose tolerance. Glucose intolerance, in general metabolic syndrome is caused by suppression of insulin release from the pancreas and suppression of insulin sensitivity of the target tissues. Several studies have suggested that impaired glucose tolerance in primary aldosteronism is due to an inability of the beta cells to release insulin by potassium depletion. It was suggested glucose intolerance in PA is caused by the suppression of insulin release related to hypopotassemia and compensatory increase of insulin sensitivity is observed in PA. The increased insulin secretory capacity associated with correction of negative potassium balance may account for the increase in plasma leptin after curing primary aldosteronism. The conclusion with respect to the possible causal relationship between DM and PA, however, can be obtained after the evaluation of the effect of surgical /pharmacological treatment of PA. From July 2005 to July 2008, patients with primary aldosteronism, hospitalized for a comprehensive study of the subtypes of primary aldosteronism before operation will receive informed consent about the insulin sensitivity test. In the present study, we measured insulin sensitivity via the ability to release insulin by the 75 g oral glucose tolerance test (OGTT) in PA to clarify the mechanisms of glucose intolerance in PA. Seventy-five gram OGTT was performed in PA before and after adrenalectomy. Within one minute, 75 g of glucose dissolved in 200 cc water was ingested. Venous blood samples were drawn at 0, 60, 120 minutes for determination of plasma glucose and plasma insulin levels. Serum potassium levels were measures at 0 minutes. Furthermore, the adipokines, HOMA, QUICKI, leptin, adiponectin, homocystine, C-reactive protein, proinflammatory cytokine and adhesion molecules were also measured.
<P>PROBLEM TO BE SOLVED: To improve conventional vaccinations and gene therapy techniques.  <P>SOLUTION: A method of making a microparticle that contains DNA coding for a polypeptide is described, in which a solvent extraction method is used and solvent extraction takes place at an elevated temperature. Oral administration of the microparticle leads to its expression. DNA coding for an immunogen is suitable for stimulating antibody formation in a recipient, and DNA coding for a non-immunogenic polypeptide is for gene therapy applications. DNA is incorporated into the microparticle without destruction of its function.  <P>COPYRIGHT: (C)2011,JPO&INPIT